Kandis Backus is a dynamic Senior Medical Scientist at Gilead Sciences, where she leverages her decade-long expertise in research and development to drive impactful initiatives in the field of HIV care. With a strong foundation in advanced academia, Kandis has established herself as a Subject...
Kandis Backus is a dynamic Senior Medical Scientist at Gilead Sciences, where she leverages her decade-long expertise in research and development to drive impactful initiatives in the field of HIV care. With a strong foundation in advanced academia, Kandis has established herself as a Subject Matter Expert in medical management and medication access, focusing on enhancing patient education and care for individuals living with HIV. Her role involves a multifaceted approach, partnering with clinicians, researchers, and healthcare providers to deliver comprehensive education and research support aimed at improving the quality of life for patients while actively working to reduce the stigma associated with HIV.
Currently, Kandis is deeply involved in Gilead's Phase IV program, where she plays a pivotal role in site selection and the implementation of clinical studies that assess the real-world effectiveness of Gilead's products. Her analytical skills are instrumental in interpreting complex data sets, enabling her to provide evidence-based insights that inform clinical inquiries and enhance the understanding of Gilead's therapeutic offerings. Additionally, Kandis’s expertise in resource allocation and her integrative genomic approach allow her to contribute significantly to innovative projects such as the PrEP program, which aims to expand access to preventive measures for at-risk populations.
Kandis is not only proficient in advanced scientific techniques, including chromatography and PCR, but she also excels in coaching and mentoring colleagues, fostering a collaborative environment that promotes continuous learning and professional growth. Her commitment to improving patient outcomes and her ability to navigate the complexities of pharmaceutical access make her a valuable asset to Gilead Sciences and the broader healthcare community.
